SARS-CoV-2 therapy (Secarna)

N/A

Report date: 2024/09/13 13:57:21
NME

Base Information

Drug NameSARS-CoV-2 therapy (Secarna)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSecarna Pharmaceuticals GmbH & Co KGSun Yat-Sen University
China Registration ClassN/A

Develop Information

Active CompaniesSun Yat-Sen UniversitySecarna Pharmaceuticals GmbH & Co KG
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A